Nature Communications (Jun 2021)
Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer
- Nicholas J. Brady,
- Alyssa M. Bagadion,
- Richa Singh,
- Vincenza Conteduca,
- Lucie Van Emmenis,
- Elisa Arceci,
- Hubert Pakula,
- Ryan Carelli,
- Francesca Khani,
- Martin Bakht,
- Michael Sigouros,
- Rohan Bareja,
- Andrea Sboner,
- Olivier Elemento,
- Scott Tagawa,
- David M. Nanus,
- Massimo Loda,
- Himisha Beltran,
- Brian Robinson,
- David S. Rickman
Affiliations
- Nicholas J. Brady
- Department of Pathology and Laboratory Medicine, Weill Cornell Medicine
- Alyssa M. Bagadion
- Department of Pathology and Laboratory Medicine, Weill Cornell Medicine
- Richa Singh
- Department of Pathology and Laboratory Medicine, Weill Cornell Medicine
- Vincenza Conteduca
- Department of Medical Oncology, Dana Farber Cancer Institute
- Lucie Van Emmenis
- Department of Pathology and Laboratory Medicine, Weill Cornell Medicine
- Elisa Arceci
- Department of Pathology and Laboratory Medicine, Weill Cornell Medicine
- Hubert Pakula
- Department of Pathology and Laboratory Medicine, Weill Cornell Medicine
- Ryan Carelli
- Department of Pathology and Laboratory Medicine, Weill Cornell Medicine
- Francesca Khani
- Department of Pathology and Laboratory Medicine, Weill Cornell Medicine
- Martin Bakht
- Department of Medical Oncology, Dana Farber Cancer Institute
- Michael Sigouros
- Caryl and Israel Englander Institute for Precision Medicine, New York-Presbyterian Hospital, Weill Cornell Medicine
- Rohan Bareja
- Department of Physiology and Biophysics, Weill Cornell Medicine
- Andrea Sboner
- Department of Pathology and Laboratory Medicine, Weill Cornell Medicine
- Olivier Elemento
- Caryl and Israel Englander Institute for Precision Medicine, New York-Presbyterian Hospital, Weill Cornell Medicine
- Scott Tagawa
- Meyer Cancer Center, Weill Cornell Medicine
- David M. Nanus
- Meyer Cancer Center, Weill Cornell Medicine
- Massimo Loda
- Department of Pathology and Laboratory Medicine, Weill Cornell Medicine
- Himisha Beltran
- Department of Medical Oncology, Dana Farber Cancer Institute
- Brian Robinson
- Department of Pathology and Laboratory Medicine, Weill Cornell Medicine
- David S. Rickman
- Department of Pathology and Laboratory Medicine, Weill Cornell Medicine
- DOI
- https://doi.org/10.1038/s41467-021-23780-y
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 17
Abstract
The heterogeneity of tumor evolution from AR-positive, adenocarcinoma to AR-negative, neuroendocrine prostate cancer (NEPC) is not fully characterized. Here the authors generate a mouse model to show that Rb1 loss and MYCN overexpression accelerates the progression to AR-negative NEPC and identify emergence of distinct subpopulations of NEPC cells.
